|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2008-1-9
|
|
pubmed:abstractText |
Transcatheter arterial embolization (TAE) has been recognized as an effective palliative treatment option for advanced hepatocellular carcinoma (HCC). However, no effective alternative treatments for TAE-refractory HCC have yet been established. The aim of this study was to evaluate the antitumor activity and toxicity of transcatheter arterial infusion chemotherapy using an epirubicin-Lipiodol emulsion in patients with TAE-refractory HCC.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0344-5704
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
61
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
683-8
|
|
pubmed:meshHeading |
pubmed-meshheading:17541589-Adult,
pubmed-meshheading:17541589-Aged,
pubmed-meshheading:17541589-Aged, 80 and over,
pubmed-meshheading:17541589-Antibiotics, Antineoplastic,
pubmed-meshheading:17541589-Carcinoma, Hepatocellular,
pubmed-meshheading:17541589-Catheterization, Peripheral,
pubmed-meshheading:17541589-Disease-Free Survival,
pubmed-meshheading:17541589-Embolization, Therapeutic,
pubmed-meshheading:17541589-Emulsions,
pubmed-meshheading:17541589-Epirubicin,
pubmed-meshheading:17541589-Female,
pubmed-meshheading:17541589-Humans,
pubmed-meshheading:17541589-Infusions, Intra-Arterial,
pubmed-meshheading:17541589-Iodized Oil,
pubmed-meshheading:17541589-Liver Neoplasms,
pubmed-meshheading:17541589-Male,
pubmed-meshheading:17541589-Middle Aged,
pubmed-meshheading:17541589-alpha-Fetoproteins
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
A phase II trial of transcatheter arterial infusion chemotherapy with an epirubicin-Lipiodol emulsion for advanced hepatocellular carcinoma refractory to transcatheter arterial embolization.
|
|
pubmed:affiliation |
Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase II
|
